Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 6 | 2021 | 217 | 1.200 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 53 | 0.940 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2024 | 13 | 0.870 |
Why?
|
| Hodgkin Disease | 1 | 2024 | 56 | 0.850 |
Why?
|
| Brain Diseases | 1 | 2024 | 75 | 0.810 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 377 | 0.710 |
Why?
|
| Crotonates | 1 | 2020 | 4 | 0.690 |
Why?
|
| Toluidines | 1 | 2020 | 4 | 0.690 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 204 | 0.540 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 218 | 0.530 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 8 | 0.480 |
Why?
|
| Etanercept | 1 | 2015 | 32 | 0.480 |
Why?
|
| Sarcoidosis | 1 | 2015 | 34 | 0.460 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 57 | 0.460 |
Why?
|
| Uveitis | 1 | 2015 | 34 | 0.460 |
Why?
|
| Cognition Disorders | 1 | 2015 | 220 | 0.430 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 220 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 613 | 0.390 |
Why?
|
| Ganglia, Spinal | 2 | 2008 | 30 | 0.360 |
Why?
|
| Neuralgia | 2 | 2018 | 22 | 0.330 |
Why?
|
| Nerve Regeneration | 1 | 2008 | 36 | 0.290 |
Why?
|
| Morphine | 1 | 2008 | 59 | 0.290 |
Why?
|
| Axons | 1 | 2008 | 123 | 0.280 |
Why?
|
| Circle of Willis | 1 | 2024 | 7 | 0.220 |
Why?
|
| Cerebrovascular Circulation | 1 | 2024 | 178 | 0.200 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 33 | 0.200 |
Why?
|
| Hemorrhage | 1 | 2024 | 267 | 0.190 |
Why?
|
| Adult | 6 | 2024 | 16668 | 0.190 |
Why?
|
| Homeostasis | 1 | 2024 | 367 | 0.180 |
Why?
|
| Hydroxybutyrates | 1 | 2020 | 11 | 0.170 |
Why?
|
| Nitriles | 1 | 2020 | 69 | 0.170 |
Why?
|
| Female | 9 | 2024 | 32560 | 0.160 |
Why?
|
| Alcoholism | 1 | 2021 | 319 | 0.150 |
Why?
|
| Dystonia | 1 | 2018 | 13 | 0.150 |
Why?
|
| Sjogren's Syndrome | 1 | 2018 | 24 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 179 | 0.150 |
Why?
|
| Humans | 13 | 2024 | 62866 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2017 | 86 | 0.130 |
Why?
|
| Mothers | 1 | 2020 | 275 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 52 | 0.130 |
Why?
|
| Infliximab | 1 | 2015 | 49 | 0.120 |
Why?
|
| Patient Participation | 1 | 2017 | 229 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 664 | 0.120 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 160 | 0.120 |
Why?
|
| Methotrexate | 1 | 2015 | 80 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 402 | 0.110 |
Why?
|
| Health Personnel | 1 | 2017 | 363 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 308 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 233 | 0.100 |
Why?
|
| Middle Aged | 4 | 2021 | 17390 | 0.080 |
Why?
|
| Aged | 3 | 2020 | 14273 | 0.080 |
Why?
|
| Male | 4 | 2021 | 29546 | 0.080 |
Why?
|
| Receptors, Opioid | 1 | 2008 | 16 | 0.070 |
Why?
|
| Anura | 1 | 2008 | 8 | 0.070 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2008 | 21 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 75 | 0.070 |
Why?
|
| Microscopy | 1 | 2008 | 91 | 0.070 |
Why?
|
| Immune System | 1 | 2008 | 130 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5598 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2549 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 964 | 0.050 |
Why?
|
| Social Class | 1 | 2021 | 133 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2020 | 11 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 86 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 104 | 0.040 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.040 |
Why?
|
| Salivary Glands, Minor | 1 | 2018 | 3 | 0.040 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 6 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 364 | 0.040 |
Why?
|
| Primary Dysautonomias | 1 | 2018 | 7 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2018 | 21 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2018 | 38 | 0.040 |
Why?
|
| Syncope | 1 | 2018 | 42 | 0.040 |
Why?
|
| Migraine Disorders | 1 | 2018 | 41 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 476 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 83 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 258 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 123 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 160 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 299 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1623 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 775 | 0.030 |
Why?
|
| Natalizumab | 1 | 2014 | 11 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 253 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2014 | 34 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 58 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 86 | 0.030 |
Why?
|
| Rituximab | 1 | 2014 | 84 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2326 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 173 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 3263 | 0.020 |
Why?
|
| Child | 1 | 2020 | 4478 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 20612 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4656 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7745 | 0.020 |
Why?
|
Berrios Morales's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(95)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_